solo para uso en investigación
Cat. No.S2111
| Dianas relacionadas | VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit |
|---|---|
| Otros EGFR Inhibidores | Lazertinib (YH25448) Icotinib Hydrochloride Sunvozertinib AG-490 AG-1478 Canertinib (CI-1033) WZ4002 Rociletinib (CO-1686) Poziotinib (NOV120101, HM781-36B) Genistein |
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| LB2241-RCC | Growth Inhibition Assay | IC50=1.15403 μM | SANGER | |||
| TE-9 | Growth Inhibition Assay | IC50=0.74453 μM | SANGER | |||
| A388 | Growth Inhibition Assay | IC50=0.72258 μM | SANGER | |||
| TE-12 | Growth Inhibition Assay | IC50=0.49057 μM | SANGER | |||
| EKVX | Growth Inhibition Assay | IC50=0.44874 μM | SANGER | |||
| BB30-HNC | Growth Inhibition Assay | IC50=0.24654 μM | SANGER | |||
| BT-474 | Growth Inhibition Assay | IC50=0.21315 μM | SANGER | |||
| DSH1 | Growth Inhibition Assay | IC50=0.09396 μM | SANGER | |||
| ECC12 | Growth Inhibition Assay | IC50=0.09231 μM | SANGER | |||
| OCUB-M | Growth Inhibition Assay | IC50=0.0574 μM | SANGER | |||
| HCC2218 | Growth Inhibition Assay | IC50=0.05326 μM | SANGER | |||
| NCI-H1648 | Growth Inhibition Assay | IC50=0.02544 μM | SANGER | |||
| LB996-RCC | Growth Inhibition Assay | IC50=1.36228 μM | SANGER | |||
| LC-1F | Growth Inhibition Assay | IC50=1.38244 μM | SANGER | |||
| TE-6 | Growth Inhibition Assay | IC50=1.55201 μM | SANGER | |||
| A253 | Growth Inhibition Assay | IC50=1.97335 μM | SANGER | |||
| OS-RC-2 | Growth Inhibition Assay | IC50=1.99199 μM | SANGER | |||
| TE-1 | Growth Inhibition Assay | IC50=2.0483 μM | SANGER | |||
| RL95-2 | Growth Inhibition Assay | IC50=3.1567 μM | SANGER | |||
| LS-513 | Growth Inhibition Assay | IC50=3.40041 μM | SANGER | |||
| DJM-1 | Growth Inhibition Assay | IC50=3.46975 μM | SANGER | |||
| NMC-G1 | Growth Inhibition Assay | IC50=3.54501 μM | SANGER | |||
| TE-10 | Growth Inhibition Assay | IC50=3.55356 μM | SANGER | |||
| TE-5 | Growth Inhibition Assay | IC50=4.0373 μM | SANGER | |||
| TK10 | Growth Inhibition Assay | IC50=4.16522 μM | SANGER | |||
| UACC-812 | Growth Inhibition Assay | IC50=4.56153 μM | SANGER | |||
| SW962 | Growth Inhibition Assay | IC50=5.02159 μM | SANGER | |||
| SW954 | Growth Inhibition Assay | IC50=5.39245 μM | SANGER | |||
| COLO-668 | Growth Inhibition Assay | IC50=5.72667 μM | SANGER | |||
| LB1047-RCC | Growth Inhibition Assay | IC50=5.80046 μM | SANGER | |||
| NB5 | Growth Inhibition Assay | IC50=6.21001 μM | SANGER | |||
| NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=6.26561 μM | SANGER | |||
| IST-MEL1 | Growth Inhibition Assay | IC50=6.43694 μM | SANGER | |||
| GI-1 | Growth Inhibition Assay | IC50=6.51682 μM | SANGER | |||
| TGBC1TKB | Growth Inhibition Assay | IC50=7.07183 μM | SANGER | |||
| GT3TKB | Growth Inhibition Assay | IC50=7.22744 μM | SANGER | |||
| EVSA-T | Growth Inhibition Assay | IC50=7.42811 μM | SANGER | |||
| D-502MG | Growth Inhibition Assay | IC50=7.48894 μM | SANGER | |||
| TE-8 | Growth Inhibition Assay | IC50=7.76159 μM | SANGER | |||
| OVCAR-4 | Growth Inhibition Assay | IC50=9.11675 μM | SANGER | |||
| D-336MG | Growth Inhibition Assay | IC50=9.47395 μM | SANGER | |||
| GCIY | Growth Inhibition Assay | IC50=9.5742 μM | SANGER | |||
| KS-1 | Growth Inhibition Assay | IC50=9.66287 μM | SANGER | |||
| HCC2998 | Growth Inhibition Assay | IC50=9.96307 μM | SANGER | |||
| D-247MG | Growth Inhibition Assay | IC50=9.98291 μM | SANGER | |||
| TE-15 | Growth Inhibition Assay | IC50=10.245 μM | SANGER | |||
| IST-MES1 | Growth Inhibition Assay | IC50=10.2565 μM | SANGER | |||
| ETK-1 | Growth Inhibition Assay | IC50=10.623 μM | SANGER | |||
| RCC10RGB | Growth Inhibition Assay | IC50=10.961 μM | SANGER | |||
| KNS-42 | Growth Inhibition Assay | IC50=11.7255 μM | SANGER | |||
| LB771-HNC | Growth Inhibition Assay | IC50=12.1712 μM | SANGER | |||
| SR | Growth Inhibition Assay | IC50=12.2064 μM | SANGER | |||
| NCI-H1355 | Growth Inhibition Assay | IC50=12.8985 μM | SANGER | |||
| ES6 | Growth Inhibition Assay | IC50=13.078 μM | SANGER | |||
| SK-NEP-1 | Growth Inhibition Assay | IC50=13.2577 μM | SANGER | |||
| D-392MG | Growth Inhibition Assay | IC50=13.6428 μM | SANGER | |||
| NB7 | Growth Inhibition Assay | IC50=14.2374 μM | SANGER | |||
| SK-LMS-1 | Growth Inhibition Assay | IC50=14.5145 μM | SANGER | |||
| SK-UT-1 | Growth Inhibition Assay | IC50=14.7889 μM | SANGER | |||
| CA46 | Growth Inhibition Assay | IC50=15.0586 μM | SANGER | |||
| IST-SL2 | Growth Inhibition Assay | IC50=15.1901 μM | SANGER | |||
| BC-1 | Growth Inhibition Assay | IC50=15.3314 μM | SANGER | |||
| LS-123 | Growth Inhibition Assay | IC50=15.8173 μM | SANGER | |||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=16.0924 μM | SANGER | |||
| MZ1-PC | Growth Inhibition Assay | IC50=16.7313 μM | SANGER | |||
| LB647-SCLC | Growth Inhibition Assay | IC50=16.9372 μM | SANGER | |||
| NCI-H1694 | Growth Inhibition Assay | IC50=17.1529 μM | SANGER | |||
| NCI-H322M | Growth Inhibition Assay | IC50=17.4366 μM | SANGER | |||
| ES7 | Growth Inhibition Assay | IC50=18.3914 μM | SANGER | |||
| LC-2-ad | Growth Inhibition Assay | IC50=18.4386 μM | SANGER | |||
| SF268 | Growth Inhibition Assay | IC50=18.7409 μM | SANGER | |||
| RPMI-8402 | Growth Inhibition Assay | IC50=19.0742 μM | SANGER | |||
| HCE-T | Growth Inhibition Assay | IC50=20.2344 μM | SANGER | |||
| A101D | Growth Inhibition Assay | IC50=20.8587 μM | SANGER | |||
| MRK-nu-1 | Growth Inhibition Assay | IC50=20.913 μM | SANGER | |||
| LXF-289 | Growth Inhibition Assay | IC50=21.038 μM | SANGER | |||
| NALM-6 | Growth Inhibition Assay | IC50=21.1967 μM | SANGER | |||
| DOHH-2 | Growth Inhibition Assay | IC50=21.4813 μM | SANGER | |||
| EW-16 | Growth Inhibition Assay | IC50=22.1402 μM | SANGER | |||
| A4-Fuk | Growth Inhibition Assay | IC50=22.2149 μM | SANGER | |||
| HD-MY-Z | Growth Inhibition Assay | IC50=22.3965 μM | SANGER | |||
| SKM-1 | Growth Inhibition Assay | IC50=22.7351 μM | SANGER | |||
| DMS-153 | Growth Inhibition Assay | IC50=23.4204 μM | SANGER | |||
| LB373-MEL-D | Growth Inhibition Assay | IC50=23.5452 μM | SANGER | |||
| LP-1 | Growth Inhibition Assay | IC50=23.8097 μM | SANGER | |||
| GI-ME-N | Growth Inhibition Assay | IC50=24.292 μM | SANGER | |||
| MPP-89 | Growth Inhibition Assay | IC50=25.2036 μM | SANGER | |||
| U-698-M | Growth Inhibition Assay | IC50=25.2503 μM | SANGER | |||
| HC-1 | Growth Inhibition Assay | IC50=25.6418 μM | SANGER | |||
| HCC2157 | Growth Inhibition Assay | IC50=25.673 μM | SANGER | |||
| MOLT-4 | Growth Inhibition Assay | IC50=26.273 μM | SANGER | |||
| LS-411N | Growth Inhibition Assay | IC50=26.3369 μM | SANGER | |||
| Becker | Growth Inhibition Assay | IC50=26.5181 μM | SANGER | |||
| NCI-H23 | Growth Inhibition Assay | IC50=26.7575 μM | SANGER | |||
| IST-SL1 | Growth Inhibition Assay | IC50=27.3867 μM | SANGER | |||
| MZ2-MEL | Growth Inhibition Assay | IC50=27.4566 μM | SANGER | |||
| RKO | Growth Inhibition Assay | IC50=28.1446 μM | SANGER | |||
| TE-441-T | Growth Inhibition Assay | IC50=28.789 μM | SANGER | |||
| EW-24 | Growth Inhibition Assay | IC50=29.1259 μM | SANGER | |||
| no-10 | Growth Inhibition Assay | IC50=29.1631 μM | SANGER | |||
| D-542MG | Growth Inhibition Assay | IC50=29.9221 μM | SANGER | |||
| ST486 | Growth Inhibition Assay | IC50=30.6451 μM | SANGER | |||
| KURAMOCHI | Growth Inhibition Assay | IC50=30.8057 μM | SANGER | |||
| ES8 | Growth Inhibition Assay | IC50=31.5972 μM | SANGER | |||
| BL-41 | Growth Inhibition Assay | IC50=32.1054 μM | SANGER | |||
| NB6 | Growth Inhibition Assay | IC50=32.3855 μM | SANGER | |||
| NCI-H1304 | Growth Inhibition Assay | IC50=32.4967 μM | SANGER | |||
| MS-1 | Growth Inhibition Assay | IC50=32.7751 μM | SANGER | |||
| MFH-ino | Growth Inhibition Assay | IC50=34.3224 μM | SANGER | |||
| NOS-1 | Growth Inhibition Assay | IC50=34.6748 μM | SANGER | |||
| HUTU-80 | Growth Inhibition Assay | IC50=35.3667 μM | SANGER | |||
| EB2 | Growth Inhibition Assay | IC50=36.6189 μM | SANGER | |||
| L-540 | Growth Inhibition Assay | IC50=37.2308 μM | SANGER | |||
| NCI-H747 | Growth Inhibition Assay | IC50=38.8846 μM | SANGER | |||
| NCI-H446 | Growth Inhibition Assay | IC50=39.9651 μM | SANGER | |||
| MOLT-16 | Growth Inhibition Assay | IC50=42.415 μM | SANGER | |||
| BC-3 | Growth Inhibition Assay | IC50=45.4896 μM | SANGER | |||
| SJSA-1 | Growth Inhibition Assay | IC50=45.5474 μM | SANGER | |||
| BB65-RCC | Growth Inhibition Assay | IC50=45.666 μM | SANGER | |||
| SNB75 | Growth Inhibition Assay | IC50=46.018 μM | SANGER | |||
| SKBR3 | Cytotoxicity assay | Cytotoxicity against human SKBR3 cells overexpressing HER2 by resazurin dye reduction assay, IC50 = 0.002 μM. | 21080629 | |||
| SKOV3 | Cytotoxicity assay | Cytotoxicity against human SKOV3 cells overexpressing HER2 by resazurin dye reduction assay, IC50 = 0.003 μM. | 21080629 | |||
| CAL27 | Cytotoxicity assay | Cytotoxicity against human CAL27 cells overexpressing EGFR by resazurin dye reduction assay, IC50 = 0.007 μM. | 21080629 | |||
| 4T1 | Cytotoxicity assay | Cytotoxicity against mouse triple negative 4T1 cells, IC50 = 0.01037 μM. | 24890652 | |||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay, IC50 = 0.011 μM. | 25151582 | ||
| SKBR3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay, IC50 = 0.017 μM. | 19028425 | ||
| MDA-MB-231 | Cytotoxicity assay | Cytotoxicity against human triple negative MDA-MB-231 cells, IC50 = 0.02 μM. | 24890652 | |||
| BT474 | Antiproliferative assay | Antiproliferative activity against human BT474 cells overexpressing ErB2, IC50 = 0.025 μM. | 18653333 | |||
| BT474 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human BT474 cells after 72 hrs by methylene blue staining-based method, IC50 = 0.025 μM. | 21887403 | ||
| HEK293 | Function assay | Inhibition of recombinant human C-terminal His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells by ELISA, IC50 = 0.02706 μM. | 28711703 | |||
| HEK293 | Function assay | Inhibition of recombinant human N-terminal His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells by ELISA, IC50 = 0.0271 μM. | 29421573 | |||
| HepG2 | Function assay | Inhibition of EGFR in human HepG2 cells, IC50 = 0.0271 μM. | 30096580 | |||
| SKBR3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay, IC50 = 0.029 μM. | 19888761 | ||
| SKBR3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SKBR3 cells overexpressing HER-2 gene after 72 hrs by SRB assay, IC50 = 0.029 μM. | 22372864 | ||
| MDA-MB-435 | Cytotoxicity assay | Cytotoxicity against human MDA-MB-435 cells, IC50 = 0.0297 μM. | 24890652 | |||
| SKBR3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SKBR3 cells assessed as inhibition of cell growth after 72 hrs by sulforhodamine B assay, IC50 = 0.0301 μM. | 25305330 | ||
| BT474 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BT474 cells expressing Her2 assessed as reduction in cell viability after 72 hrs by cell titer-glo luminescence assay, IC50 = 0.031 μM. | 27288180 | ||
| CAL27 | Function assay | 16 hrs | Inhibition of EGF-induced EGFR phosphorylation in human CAL27 cells overexpressing EGFR after 16 hrs by Western blot, IC50 = 0.032 μM. | 21080629 | ||
| NCI-N87 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-N87 cells expressing HER-2 after 72 hrs by SRB assay, IC50 = 0.036 μM. | 22372864 | ||
| insect cells | Function assay | 5 mins | Inhibition of recombinant human EGFR L858R mutant expressed in baculovirus infected insect cells preincubated for 5 mins followed by ATP addition and measured after 30 mins by HTRF assay, IC50 = 0.03755 μM. | 30096580 | ||
| SK-BR-3 | Antiproliferative assay | Antiproliferative activity against human SK-BR-3 cells after hrs by ATP content assay, IC50 = 0.04 μM. | 20143778 | |||
| MDA-MB-175 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-175 cells expressing Src, Ret and low HER-2 after 72 hrs by SRB assay, IC50 = 0.0444 μM. | 22372864 | ||
| A431 | Function assay | Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA, IC50 = 0.052 μM. | 20346655 | |||
| SK-BR-3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SK-BR-3 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay, IC50 = 0.06 μM. | 27769671 | ||
| BT474 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BT474 cells assessed as inhibition of cell growth after 72 hrs by sulforhodamine B assay, IC50 = 0.0639 μM. | 25305330 | ||
| MCF7 | Cytotoxicity assay | Cytotoxicity against human ER-positive MCF7 cells, IC50 = 0.0649 μM. | 24890652 | |||
| MDA-MB-468 | Cytotoxicity assay | Cytotoxicity against human triple negative MDA-MB-468 cells, IC50 = 0.0832 μM. | 24890652 | |||
| NCI-N87 | Antiproliferative assay | 3 days | Antiproliferative activity against human NCI-N87 cells after 3 days by methylene blue staining, IC50 = 0.09 μM. | 22101132 | ||
| N87 | Function assay | Inhibition of ErbB2 intracellular phosphorylation in human N87 cells by ELISA, IC50 = 0.1 μM. | 20346655 | |||
| BT474 | Antiproliferative assay | 3 days | Antiproliferative activity against human BT474 cells after 3 days by methylene blue staining, IC50 = 0.1 μM. | 22101132 | ||
| Calu3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Calu3 cells after 72 hrs by MTT assay, IC50 = 0.1 μM. | 28092860 | ||
| BT474 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human BT474 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay, IC50 = 0.1 μM. | 27769671 | ||
| A431 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A431 cells after 72 hrs by SRB assay, IC50 = 0.104 μM. | 19888761 | ||
| A431 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A431 cells overexpressing HER-1 gene after 72 hrs by SRB assay, IC50 = 0.104 μM. | 22372864 | ||
| HeLa | Antiproliferative assay | 12 hrs | Antiproliferative activity against human HeLa cells after 12 hrs by MTT assay, IC50 = 0.12 μM. | 26652482 | ||
| MIAPaCa | Function assay | Inhibition of ERBb2 phosphorylation in human MIAPaCa cells by ELISA, IC50 = 0.14 μM. | 20817523 | |||
| A431 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A431 cells expressing EGFR/HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay, IC50 = 0.15 μM. | 27769671 | ||
| MDA-MB-453 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell growth after 72 hrs by sulforhodamine B assay, IC50 = 0.19 μM. | 25305330 | ||
| BT474 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BT474 cells assessed as growth inhibition after 72 hrs by calcein-AM dye based fluorescence assay, GI50 = 0.2 μM. | 29089259 | ||
| B16F10 | Antiproliferative assay | 12 hrs | Antiproliferative activity against mouse B16F10 cells after 12 hrs by MTT assay, IC50 = 0.21 μM. | 26652482 | ||
| Sf21 | Function assay | 5 mins | Inhibition of N-terminal GST-tagged recombinant human EGFR T790M mutant expressed in baculovirus infected Sf21 insect cells preincubated for 5 mins followed by ATP addition and measured after 30 mins by HTRF assay, IC50 = 0.22489 μM. | 30096580 | ||
| Calu3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Calu3 cells assessed as inhibition of cell growth after 72 hrs by sulforhodamine B assay, IC50 = 0.23 μM. | 25305330 | ||
| DIFI | Cytotoxicity assay | 4 days | Cytotoxicity against human DIFI cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 0.235 μM. | 22169601 | ||
| HepG2 | Antiproliferative assay | 12 hrs | Antiproliferative activity against human HepG2 cells after 12 hrs by MTT assay, IC50 = 0.27 μM. | 26652482 | ||
| EOL-1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human EOL-1 cells assessed as growth inhibition after 72 hrs by calcein-AM dye based fluorescence assay, GI50 = 0.41 μM. | 29089259 | ||
| MIAPaCa | Function assay | Inhibition of EGFR phosphorylation in human MIAPaCa cells by ELISA, IC50 = 0.433 μM. | 20817523 | |||
| MCF7 | Antiproliferative assay | 12 hrs | Antiproliferative activity against human MCF7 cells after 12 hrs by MTT assay, IC50 = 0.47 μM. | 26652482 | ||
| SKBR3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay, IC50 = 0.49 μM. | 27187856 | ||
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells expressing EGFR and KRAS mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay, IC50 = 0.51 μM. | 27769671 | ||
| CAL27 | Cytotoxicity assay | 4 days | Cytotoxicity against human CAL27 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 0.53 μM. | 22169601 | ||
| MDA-MB-453 | Cytotoxicity assay | 72 hrs | Cytotoxicity against PTEN-deficient human MDA-MB-453 cells expressing HER-2, and PIK3CA mutant after 72 hrs by SRB assay, IC50 = 0.555 μM. | 22372864 | ||
| SKOV3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth after 72 hrs by sulforhodamine B assay, IC50 = 0.59 μM. | 25305330 | ||
| HCC827 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCC827 cells harboring EGFR E746-A750 del mutant after 72 hrs by MTT assay, IC50 = 0.6 μM. | 29421573 | ||
| A431NS | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A431NS cells after 72 hrs by MTT assay, IC50 = 0.6 μM. | 28092860 | ||
| A431 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A431 cells assessed as inhibition of cell growth after 72 hrs by sulforhodamine B assay, IC50 = 0.6431 μM. | 25305330 | ||
| BT474 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by Cell Titer Glo assay, GI50 = 0.93 μM. | 26475520 | ||
| A431 | Cytotoxicity assay | Cytotoxicity against human A431 cells overexpressing EGFR by resazurin dye reduction assay, IC50 = 0.97 μM. | 21080629 | |||
| MDA-MB-361 | Cytotoxicity assay | 72 hrs | Cytotoxicity against ER activated human MDA-MB-361 cells expressing Her-2, Src and PIK3CA mutant after 72 hrs by SRB assay, IC50 = 1.029 μM. | 22372864 | ||
| GXF251L | Cytotoxicity assay | 4 days | Cytotoxicity against human GXF251L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 1.48 μM. | 22169601 | ||
| A431 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTT assay, IC50 = 2.6 μM. | 22595177 | ||
| A431 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A431 cells overexpressing EGFR after 72 hrs by MTT assay, IC50 = 2.62 μM. | 22182581 | ||
| LXFA 629L | Cytotoxicity assay | 4 days | Cytotoxicity against human LXFA 629L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 2.87 μM. | 22169601 | ||
| DU145 | Cytotoxicity assay | 4 days | Cytotoxicity against human DU145 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 2.99 μM. | 22169601 | ||
| SKOV3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SKOV3 cells overexpressing ErbB2 after 72 hrs by MTT assay, IC50 = 2.99 μM. | 22182581 | ||
| NCI-H1781 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H1781 cells expressing HER-2 G776insV_G/C after 72 hrs by SRB assay, IC50 = 3.047 μM. | 22372864 | ||
| OVXF 899L | Cytotoxicity assay | 4 days | Cytotoxicity against human OVXF 899L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 3.35 μM. | 22169601 | ||
| LXFL 529L | Cytotoxicity assay | 4 days | Cytotoxicity against human LXFL 529L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 3.51 μM. | 22169601 | ||
| LNCAP | Cytotoxicity assay | 4 days | Cytotoxicity against human LNCAP cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 3.68 μM. | 22169601 | ||
| Bel7402 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay, IC50 = 3.7 μM. | 28092860 | ||
| LXFA 526L | Cytotoxicity assay | 4 days | Cytotoxicity against human LXFA 526L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 4.21 μM. | 22169601 | ||
| NIH/3T3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay, IC50 = 4.3 μM. | 22595177 | ||
| SK-BR-3 | Antiproliferative assay | Antiproliferative activity against ErbB2 overexpressing human SK-BR-3 cells by MTT assay, IC50 = 4.35 μM. | 21570843 | |||
| UXF 1138L | Cytotoxicity assay | 4 days | Cytotoxicity against human UXF 1138L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 4.4 μM. | 22169601 | ||
| SK-BR-3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay, IC50 = 4.4 μM. | 28092860 | ||
| PC3M | Cytotoxicity assay | 4 days | Cytotoxicity against human PC3M cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 4.55 μM. | 22169601 | ||
| COLO205 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay, IC50 = 4.6 μM. | 28092860 | ||
| HT-29 | Cytotoxicity assay | 4 days | Cytotoxicity against human HT-29 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 4.62 μM. | 22169601 | ||
| A431 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay, IC50 = 4.8 μM. | 29421573 | ||
| A431 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay, IC50 = 4.8 μM. | 28711703 | ||
| A431 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A431 cells assessed as decrease in cell viability after 72 hrs by MTT assay, IG50 = 4.8 μM. | 28238614 | ||
| MCF7 | Cytotoxicity assay | 4 days | Cytotoxicity against human MCF7 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 4.83 μM. | 22169601 | ||
| MEXF 1341L | Cytotoxicity assay | 4 days | Cytotoxicity against human MEXF 1341L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 4.85 μM. | 22169601 | ||
| MCF7 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay, IC50 = 5.02 μM. | 30096580 | ||
| SKBR3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human estrogen receptor and progesterone receptor deficient SKBR3 cells expressing HER2 after 72 hrs by MTT assay, IC50 = 5.05 μM. | 23927972 | ||
| SKHEP1 | Antiproliferative assay | hrs | Antiproliferative activity against human SKHEP1 cells after hrs by ATP content assay, IC50 = 5.3 μM. | 20143778 | ||
| RKO | Cytotoxicity assay | 4 days | Cytotoxicity against human RKO cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 5.35 μM. | 22169601 | ||
| MDA-MB-231 | Antiproliferative assay | hrs | Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay, IC50 = 5.4 μM. | 20143778 | ||
| Hep3B2 | Antiproliferative assay | hrs | Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay, IC50 = 5.49 μM. | 20143778 | ||
| K562 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by calcein-AM dye based fluorescence assay, GI50 = 5.7 μM. | 29089259 | ||
| LXFA 289L | Cytotoxicity assay | 4 days | Cytotoxicity against human LXFA 289L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 5.79 μM. | 22169601 | ||
| MAXF 401NL | Cytotoxicity assay | 4 days | Cytotoxicity against human MAXF 401NL cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 5.8 μM. | 22169601 | ||
| HeLa | Cytotoxicity assay | Cytotoxicity against human HeLa cells overexpressing HDAC by resazurin dye reduction assay, IC50 = 5.9 μM. | 21080629 | |||
| HCT116 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay, IC50 = 5.92 μM. | 30096580 | ||
| 22Rv1 | Cytotoxicity assay | 4 days | Cytotoxicity against human 22Rv1 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 6.06 μM. | 22169601 | ||
| PAXF 546L | Cytotoxicity assay | 4 days | Cytotoxicity against human PAXF 546L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 6.12 μM. | 22169601 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 6.2 μM. | 28092860 | ||
| HepG2 | Antiproliferative assay | Antiproliferative activity against human HepG2 cells after hrs by ATP content assay, IC50 = 6.27 μM. | 20143778 | |||
| HepG2 | Cytotoxicity assay | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability, TC50 = 6.27 μM. | 29049963 | |||
| HepG2 | Cytotoxicity assay | Cytotoxicity against human HepG2 cells, TC50 = 6.3 μM. | 30344906 | |||
| NCI-H522 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H522 cells after 72 hrs by MTT assay, IC50 = 6.4 μM. | 28092860 | ||
| MCF7 | Antiproliferative assay | hrs | Antiproliferative activity against human MCF7 cells after hrs by ATP content assay, IC50 = 6.6 μM. | 20143778 | ||
| A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, IC50 = 6.74 μM. | 27187856 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 6.8 μM. | 29684708 | ||
| PXF 1118L | Cytotoxicity assay | 4 days | Cytotoxicity against human PXF 1118L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 6.86 μM. | 22169601 | ||
| LIXF 575L | Cytotoxicity assay | 4 days | Cytotoxicity against human LIXF 575L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 7.18 μM. | 22169601 | ||
| RXF 1781L | Cytotoxicity assay | 4 days | Cytotoxicity against human RXF 1781L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 7.67 μM. | 22169601 | ||
| MDA231 | Cytotoxicity assay | 4 days | Cytotoxicity against human MDA231 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 7.7 μM. | 22169601 | ||
| LXFL 1121L | Cytotoxicity assay | 4 days | Cytotoxicity against human LXFL 1121L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 7.73 μM. | 22169601 | ||
| RXF 393NL | Cytotoxicity assay | 4 days | Cytotoxicity against human RXF 393NL cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 7.77 μM. | 22169601 | ||
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by calcein-AM dye based fluorescence assay, GI50 = 8.1 μM. | 29089259 | ||
| PANC1 | Cytotoxicity assay | 4 days | Cytotoxicity against human PANC1 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 8.12 μM. | 22169601 | ||
| CXF 269L | Cytotoxicity assay | 4 days | Cytotoxicity against human CXF 269L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 8.36 μM. | 22169601 | ||
| NCI-H460 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay, IC50 = 8.4 μM. | 28092860 | ||
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by sulforhodamine B assay, IC50 = 8.468 μM. | 25305330 | ||
| A549 | Cytotoxicity assay | Cytotoxicity against human A549 cells overexpressing HDAC by resazurin dye reduction assay, IC50 = 8.5 μM. | 21080629 | |||
| NCI-H1975 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay, IC50 = 9.08 μM. | 28711703 | ||
| NCI-H1975 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTT assay, IG50 = 9.08 μM. | 28238614 | ||
| RXF 486L | Cytotoxicity assay | 4 days | Cytotoxicity against human RXF 486L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 9.1 μM. | 22169601 | ||
| Saos2 | Cytotoxicity assay | 4 days | Cytotoxicity against human Saos2 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 9.38 μM. | 22169601 | ||
| PXF 1752L | Cytotoxicity assay | 4 days | Cytotoxicity against human PXF 1752L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 9.46 μM. | 22169601 | ||
| PXF 698L | Cytotoxicity assay | 4 days | Cytotoxicity against human PXF 698L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 9.49 μM. | 22169601 | ||
| BXF T24 | Cytotoxicity assay | 4 days | Cytotoxicity against human BXF T24 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 9.65 μM. | 22169601 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 10.12 μM. | 29684708 | ||
| MEXF 462NL | Cytotoxicity assay | 4 days | Cytotoxicity against human MEXF 462NL cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 10.13 μM. | 22169601 | ||
| A2780 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay, IC50 = 10.4 μM. | 29684708 | ||
| TE671 | Cytotoxicity assay | 4 days | Cytotoxicity against human TE671 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 10.95 μM. | 22169601 | ||
| RAW264.7 | Antileishmanial assay | 96 hrs | Antileishmanial activity against luciferase-expressing Leishmania major amastigotes infected in mouse RAW264.7 cells after 96 hrs by luminescence assay, EC50 = 11 μM. | 28337329 | ||
| PAXF 1657L | Cytotoxicity assay | 4 days | Cytotoxicity against human PAXF 1657L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 11.11 μM. | 22169601 | ||
| MEXF 276L | Cytotoxicity assay | 4 days | Cytotoxicity against human MEXF 276L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 11.37 μM. | 22169601 | ||
| MKN45 | Cytotoxicity assay | 4 days | Cytotoxicity against human MKN45 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 11.48 μM. | 22169601 | ||
| BXF 1352L | Cytotoxicity assay | 4 days | Cytotoxicity against human BXF 1352L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 11.53 μM. | 22169601 | ||
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay, IC50 = 11.71 μM. | 30096580 | ||
| BXF 1218L | Cytotoxicity assay | 4 days | Cytotoxicity against human BXF 1218L cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 11.77 μM. | 22169601 | ||
| Caco | Cytotoxicity assay | 24 hrs | Cytotoxicity against human Caco cells after 24 hrs by SRB assay, IC50 = 12.11 μM. | 30096580 | ||
| SW480 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay, IC50 = 12.58 μM. | 29421573 | ||
| SW480 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay, IC50 = 12.58 μM. | 28711703 | ||
| SW480 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 72 hrs by MTT assay, IG50 = 12.58 μM. | 28238614 | ||
| NCI-H1975 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay, IC50 = 12.68 μM. | 29421573 | ||
| 3T3 | Antitrypanosomal assay | 48 hrs | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in rat 3T3 cells after 48 hrs by chlorophenol red-beta-D-galactopyranoside based assay, EC50 = 13 μM. | 28337329 | ||
| HCT116 | Cytotoxicity assay | 4 days | Cytotoxicity against human HCT116 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 13.14 μM. | 22169601 | ||
| OVCAR3 | Cytotoxicity assay | 4 days | Cytotoxicity against human OVCAR3 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 13.44 μM. | 22169601 | ||
| H460 | Cytotoxicity assay | 4 days | Cytotoxicity against human H460 cells after 4 days by propidium iodide staining-based fluorometric analysis, IC50 = 13.46 μM. | 22169601 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells harboring wild type EGFR/K-ras mutant after 72 hrs by MTT assay, IC50 = 14.9 μM. | 29421573 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells harboring wild type EGFR/K-Ras mutant after 72 hrs by MTT assay, IC50 = 14.9 μM. | 28711703 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by MTT assay, IG50 = 14.9 μM. | 28238614 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells expressing pcDNA3 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay, IC50 = 15.71 μM. | 24355130 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells expressing HER2 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay, IC50 = 15.79 μM. | 24355130 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells expressing HER2delta16 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay, IC50 = 19.22 μM. | 24355130 | ||
| MDA-MB-468 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by MTT assay, IC50 = 20 μM. | 28092860 | ||
| HCC827 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by calcein-AM dye based fluorescence assay, GI50 = 22.3 μM. | 29089259 | ||
| MDA-MB-468 | Antiproliferative assay | Antiproliferative activity against EGFR overexpressing human MDA-MB-468 cells by MTT assay, IC50 = 23.46 μM. | 21570843 | |||
| HCT116 | Antiproliferative assay | Antiproliferative activity against human HCT116 cells by MTT assay, IC50 = 42.36 μM. | 21570843 | |||
| NCI-N87 | Antitumor assay | Antitumor activity against human NCI-N87 cells xenografted in athymic mouse assessed as tumor growth inhibition at 20 mg/kg, po QD for 14 days measured after 19 days | 22101132 | |||
| A431 | Function assay | 0.001 to 10 uM | 2 hrs | Inhibition of HER1 (unknown origin) expressed in human A431 cells assessed as reduction in ERK1/2 phosphorylation at 0.001 to 10 uM incubated for 2 hrs by Western blot method | 25305330 | |
| A431 | Function assay | 0.001 to 10 uM | 2 hrs | Inhibition of HER1 (unknown origin) expressed in human A431 cells assessed as reduction in AKT phosphorylation at 0.001 to 10 uM incubated for 2 hrs by Western blot method | 25305330 | |
| BT474 | Function assay | 0.001 to 10 uM | 2 hrs | Inhibition of HER2 (unknown origin) expressed in human BT474 cells assessed as reduction in ERK1/2 phosphorylation at 0.001 to 10 uM incubated for 2 hrs by Western blot method | 25305330 | |
| BT474 | Function assay | 0.001 to 10 uM | 2 hrs | Inhibition of HER2 (unknown origin) expressed in human BT474 cells assessed as reduction in AKT phosphorylation at 0.001 to 10 uM incubated for 2 hrs by Western blot method | 25305330 | |
| A431 | Function assay | 0.001 to 10 uM | 2 hrs | Inhibition of HER1 phosphorylation (unknown origin) expressed in human A431 cells at 0.001 to 10 uM incubated for 2 hrs by Western blot method | 25305330 | |
| BT474 | Function assay | 0.001 to 10 uM | 2 hrs | Inhibition of HER2 phosphorylation (unknown origin) expressed in human BT474 cells at 0.001 to 10 uM incubated for 2 hrs by Western blot method | 25305330 | |
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | |||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | |||
| NCI-H522 | Antitumor assay | Antitumor activity against human NCI-H522 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 100 mg/kg, ig administered once daily for 28 days relative to control | 28092860 | |||
| MCF7 | Function assay | 10 uM | 2 hrs | Inhibition of HER2 delta16 mutant autophosphorylation at Y1248 in human MCF7 cells at 10 uM after 2 hrs by Western blotting | 24355130 | |
| MCF7 | Function assay | 10 uM | 2 hrs | Inhibition of HER2 autophosphorylation at Y1248 in human MCF7 cells expressing pcDNA3 at 10 uM after 2 hrs by Western blotting | 24355130 | |
| MCF7 | Function assay | 10 uM | 2 hrs | Inhibition of EGFR autophosphorylation at Y1068 in human MCF7 cells expressing HER2delta16 at 10 uM after 2 hrs by Western blotting | 24355130 | |
| MCF7 | Function assay | 10 uM | 2 hrs | Inhibition of EGFR autophosphorylation at Y1068 in human MCF7 cells expressing HER2 at 10 uM after 2 hrs by Western blotting | 24355130 | |
| MCF7 | Function assay | 10 uM | 2 hrs | Inhibition of EGFR autophosphorylation at Y1068 in human MCF7 cells expressing pcDNA3 at 10 uM after 2 hrs by Western blotting | 24355130 | |
| MCF7 | Function assay | 10 uM | 2 hrs | Inhibition of HER2 autophosphorylation at Y1248 in human MCF7 cells at 10 uM after 2 hrs by Western blotting | 24355130 | |
| A549 | Function assay | 50 uM | 2 hrs | Inhibition of EGFR phosphorylation at Y1068 in human A549 cells at 50 uM preincubated for 2 hrs followed by EGF induction measured after 10 mins by Western blot method | 28238614 | |
| A549 | Function assay | 50 uM | 2 hrs | Inhibition of EGFR phosphorylation at Tyr residue in human A549 cells at 50 uM preincubated for 2 hrs followed by EGF induction measured after 10 mins by Western blot method | 28238614 | |
| LLC | Antitumor assay | Antitumor activity against mouse LLC cells implanted in in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg, po qd for 14 days | 27187856 | |||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 581.06 | Fórmula | C29H26ClFN4O4S |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 231277-92-2 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | GSK572016, GW2016 | Smiles | CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl | ||
|
In vitro |
DMSO
: 100 mg/mL
(172.09 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
ErbB2
(Cell-free assay) 9.2 nM
EGFR
(Cell-free assay) 10.8 nM
ErbB4
(Cell-free assay) 367 nM
|
|---|---|
| In vitro |
Lapatinib inhibe débilmente la actividad de ErbB4 con un IC50 de 367 nM, y muestra una selectividad >300 veces mayor para EGFR y ErbB2 sobre otras quinasas como c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2 y VEGFR2. Este compuesto inhibe significativamente la autofosforilación de los receptores EGFR y ErbB2 de manera dosis-dependiente con IC50 de 170 nM y 80 nM, respectivamente, en células HN5; así como 210 nM y 60 nM, respectivamente, en células BT474. A diferencia de OSI-774 e Iressa (ZD1839) que inhiben preferentemente el crecimiento de las células que sobreexpresan EGFR, inhibe el crecimiento tanto de las células que sobreexpresan EGFR como de las que sobreexpresan ErbB2. Este químico muestra una mayor actividad inhibidora contra las células que sobreexpresan EGFR o ErbB2 con un IC50 de 0,09-0,21 μM, en comparación con las células que expresan bajos niveles de EGFR o ErbB2 con un IC50 de 3-12 μM, y exhibe una selectividad de ~100 veces sobre las células fibroblásticas normales. Inhibe potentemente el crecimiento de las células HN5 y A-431 que sobreexpresan EGFR, así como de las células BT474 y N87 que sobreexpresan ErbB2, e induce significativamente la detención del ciclo celular en G1 de las células HN5 y la apoptosis de las células BT474, lo que se asocia con la inhibición de la fosforilación de AKT.
|
| Ensayo de quinasa |
Ensayos de quinasa in vitro
|
|
Los valores de IC50 para la inhibición de la actividad enzimática se generan midiendo la inhibición de la fosforilación de un sustrato peptídico. Los dominios intracelulares de quinasa de EGFR y ErbB2 se purifican de un sistema de expresión de baculovirus. Las reacciones de EGFR y ErbB2 se realizan en placas de poliestireno de fondo redondo de 96 pocillos en un volumen final de 45 μL. Las mezclas de reacción contienen 50 mM de ácido 4-morfolinopropanosulfónico (pH 7,5), 2 mM de MnCl2, 10 μM de ATP, 1 μCi de [γ33P] ATP/reacción, 50 μM de Péptido A [Biotina-(ácido aminohexanoico)-EEEEYFELVAKKK-CONH2], 1 mM de ditiotreitol y 1 μL de DMSO que contiene diluciones en serie de este compuesto a partir de 10 μM. La reacción se inicia añadiendo el dominio intracelular purificado del receptor tipo 1 indicado. La cantidad de enzima añadida es de 1 pmol/reacción (20 nM). Las reacciones se terminan después de 10 minutos a 23°C añadiendo 45 μL de ácido fosfórico al 0,5% en agua. La mezcla de reacción terminada (75 μL) se transfiere a placas de filtro de fosfocelulosa. Las placas se filtran y se lavan tres veces con 200 μL de ácido fosfórico al 0,5%. Se añade cóctel de centelleo (50 μL) a cada pocillo, y el ensayo se cuantifica mediante recuento en un Packard Topcount. Los valores de IC50 se generan a partir de curvas de dosis-respuesta de 10 puntos.
|
|
| In vivo |
La administración oral de Lapatinib (~100 mg/kg) dos veces al día inhibe significativamente el crecimiento de xenoinjertos BT474 y HN5 de manera dosis-dependiente.
|
Referencias |
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Western blot | ERBB2 / pERBB2 / p53 / Mdm2 / MdmX / pERK / Hsp70 pEGFR / EGFR / pAkt / Akt / pmTOR / mTOR / PARP / c-PARP p-HER2 / HER2 / p-HER3 / HER3 / p-S6 / S6 / p-4EBP1 |
|
29799521 |
| Immunofluorescence | LC3 Vimentin / E-cadherin |
|
26637440 |
| Growth inhibition assay | Cell viability (OE19) Cell viability (A431 cells) |
|
25350844 |
(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)
| Número NCT | Reclutamiento | Condiciones | Patrocinador/Colaboradores | Fecha de inicio | Fases |
|---|---|---|---|---|---|
| NCT00455039 | Withdrawn | Breast Cancer |
University of New Mexico |
July 31 2023 | Phase 1|Phase 2 |
| NCT04608409 | Active not recruiting | Ovarian Cancer |
Frederick R. Ueland M.D.|National Cancer Institute (NCI)|University of Kentucky |
March 17 2021 | Phase 1 |
| NCT03075995 | Unknown status | Breast Cancer |
Sun Yat-sen University |
April 12 2017 | Not Applicable |
| NCT02338245 | Completed | Metastatic Breast Cancer |
ASLAN Pharmaceuticals |
December 29 2014 | Phase 2 |
| NCT02294786 | Terminated | Cancer |
Novartis Pharmaceuticals|Novartis |
December 17 2014 | Phase 2 |
| NCT02158507 | Active not recruiting | Metastatic Triple Negative Breast Cancer |
University of Alabama at Birmingham|Breast Cancer Research Foundation of Alabama|GlaxoSmithKline|AbbVie |
September 2014 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
Si tiene alguna otra consulta, por favor deje un mensaje.
Pregunta 1:
If I want to use this compound via injection in tumor-bearing mice, how could I prepare the solution?
Respuesta:
For I.P. administration, the compound solution should be clear solution. It can be dissolved in 2% DMSO/30% PEG 300/5% Tween 80/ddH2O at 10 mg/ml for clear solution.